David Liston

David Liston has held various roles in the biotechnology and pharmaceutical industries since 1990. David began their career as a Quality Control Analyst at Genentech in 1990. In 1991, they moved to Systemix as a Research Associate. In 1994, they joined UCLA as a Graduate Student and Postdoctoral Fellow, where they investigated gene regulation in an early-evolving protozoan human parasite. In 2001, they became a Postdoctoral Fellow at Yale University School of Medicine, where they examined the role of the lysosomal calcium sensor Synaptotagmin VII (Syt VII) in endosome-lysosome fusion and survival of intracellular bacterial pathogens. In 2002, they became a Postdoctoral Research Associate at the Salk Institute for Biological Studies, where they investigated the mechanism by which TGF-beta signaling induces the growth control genes p15 and p21 and examined the epigenetic silencing of these genes in cancer. In 2007, they joined Protelica as a Senior Scientist and Group Leader - Protein Engineering, where they were the project lead for the Pronectin antibody mimetic platform, responsible for all aspects of the program. In 2016, they moved to ReCode Therapeutics as a Principal Scientist, then Senior Scientist II and Senior Scientist I.

David Liston received their Bachelor of Arts (B.A.) in Molecular Biology from UC San Diego between 1985 and 1990. David then went on to pursue a Doctor of Philosophy (Ph.D.) in Microbiology and Immunology from the University of California, Los Angeles between 1993 and 1999.